GlassScriptPhysician profile
Daniel James Coleman
NPI 1154776276
$4,944.43
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $998 · 2023: $1,995 · 2024: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,839.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,839.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $866.05 | 2021 | |
| Novo Nordisk INC | $754.08 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $748.11 | 2022-2024 | |
| Lilly USA, LLC | $362.68 | 2022-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $303.90 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $216.28 | 2021-2024 | Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.09 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $163.70 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $162.29 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $145.03 | 2022-2024 | |
| Gilead Sciences, INC. | $125.00 | 2023 | Vemlidy |
| Ibsa Pharma INC. | $117.81 | 2022-2023 | Tirosint, Licart |
| Abbott Laboratories | $110.65 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $106.31 | 2023-2024 | Cologuard Collection Kit |
| Tolmar, INC. | $74.67 | 2023-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $70.75 | 2022-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $50.68 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $46.69 | 2023-2024 | Trintellix |
| Sanofi-Aventis U.S. LLC | $45.14 | 2022 | |
| Xeris Pharmaceuticals, INC. | $44.65 | 2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.55 | 2023 | Xifaxan |
| Linus Health, INC. | $27.25 | 2023 | |
| Impel Pharmaceuticals INC. | $24.61 | 2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $24.07 | 2022 | |
| Supernus Pharmaceuticals, INC. | $23.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $22.44 | 2022 | |
| Medtronic, INC. | $21.40 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.26 | 2022 | |
| Lundbeck LLC | $14.87 | 2024 | Rexulti |
| Horizon Therapeutics Plc | $11.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.